Affiliation:
1. Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
Abstract
Abstract:
Alzheimer’s Disease (AD) is a multifactorial incurable neurodegenerative disorder. It is
characterized by a decline of cholinergic function in parallel with β-amyloid fibril deposition. Such
an imbalance causes severe loss in memory and cognition, leading to behavioral disturbances, depression,
and ultimately death. During the last decades, only a few approved drugs were launched
onto the market with indications for treating initial and moderate stages of AD. To date, cholinesterase
inhibitors (ChEI) are the mainstay line of treatment to ameliorate AD symptoms. Tacrine and
Donepezil are the most commonly prescribed anti-dementia drugs, given their potent inhibitory effects.
Therefore, many trials have focused on both drugs' structures to synthesize new anti-dementia
agents. This paper discusses recent trends of new AD-treating anti-dementia agents focusing on
Tacrine and Donepezil analogs and multifunctional hybrid ligands.
Publisher
Bentham Science Publishers Ltd.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献